Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanhua Fu

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Expert Review of Anti-Infective Therapy|September 28, 2022
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest ChinaXiaoyan Yang, Yanhua Fu, Xiaoxin Xie, et al.
Infectious Diseases and Therapy|October 3, 2023
Pharmacokinetics and Safety of Ainuovirine/Lamivudine/Tenofovir Combination Tablets in Young and Elderly Patients with Human Immunodeficiency Virus-1 InfectionXiaoxin Xie, Lin Gan, Yanhua Fu, et al.
Immunity, Inflammation and Disease|March 22, 2026
Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case SeriesJinhong He, Xiangxi He, Xiaoxin Xie, et al.
Immunity, Inflammation and Disease|April 5, 2024
Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort studyShujing Ma, Xiaoxin Xie, Yanhua Fu, et al.
Journal of Environmental Management|January 8, 2025
Using the Forel-Ule index (FUI) to track the water quality of subsidence water bodies across the life cycle of coal mining in eastern ChinaWenqi Chen, Lijuan Chen, Yongping Wei, et al.
AIDS (London, England)|January 28, 2025
Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week studyXiaoxin Xie, Yanhua Fu, Lin Gan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 22, 2025
Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week studyYanhua Fu, Xiaoxin Xie, Lin Gan, et al.
Journal of Medical Virology|July 4, 2026
Metabolic and Immunological Trajectories and Virological Outcomes of Ainuovirine-Based Antiretroviral Therapy: A 48-Week Longitudinal Cohort Study in Treatment-Naïve AdultsLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Frontiers in Medicine|September 15, 2025
Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest ChinaQing Wang, Xiaoxin Xie, Yanhua Fu, et al.
BMC Infectious Diseases|June 6, 2024
Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort studyLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Expert Review of Anti-Infective Therapy|September 28, 2022
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest ChinaXiaoyan Yang, Yanhua Fu, Xiaoxin Xie, et al.
Infectious Diseases and Therapy|October 3, 2023
Pharmacokinetics and Safety of Ainuovirine/Lamivudine/Tenofovir Combination Tablets in Young and Elderly Patients with Human Immunodeficiency Virus-1 InfectionXiaoxin Xie, Lin Gan, Yanhua Fu, et al.
Immunity, Inflammation and Disease|March 22, 2026
Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case SeriesJinhong He, Xiangxi He, Xiaoxin Xie, et al.
Immunity, Inflammation and Disease|April 5, 2024
Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort studyShujing Ma, Xiaoxin Xie, Yanhua Fu, et al.
Journal of Environmental Management|January 8, 2025
Using the Forel-Ule index (FUI) to track the water quality of subsidence water bodies across the life cycle of coal mining in eastern ChinaWenqi Chen, Lijuan Chen, Yongping Wei, et al.
AIDS (London, England)|January 28, 2025
Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week studyXiaoxin Xie, Yanhua Fu, Lin Gan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 22, 2025
Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week studyYanhua Fu, Xiaoxin Xie, Lin Gan, et al.
Journal of Medical Virology|July 4, 2026
Metabolic and Immunological Trajectories and Virological Outcomes of Ainuovirine-Based Antiretroviral Therapy: A 48-Week Longitudinal Cohort Study in Treatment-Naïve AdultsLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Frontiers in Medicine|September 15, 2025
Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest ChinaQing Wang, Xiaoxin Xie, Yanhua Fu, et al.
BMC Infectious Diseases|June 6, 2024
Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort studyLin Gan, Xiaoxin Xie, Yanhua Fu, et al.
Pageof 5